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Objective(s): Hepatitis C is a major cause of liver failure worldwide. Current therapies applied for 
this disease are not fully effective and produce side effects in most cases. Non-structural protein 3 
helicase (NS3) of HCV is one of the key enzymes in viral replication and infection. Therefore, this 
region is a promising target to design new drugs and therapies against HCV infection. The aim of 
this study was cloning and expression of HCV NS3 helicase fragment in Escherichia coli BL21 (DE3) 
using pET102/D-TOPO expression vector and studying immunoreactivity of the expressed antigen 
in Iranian infected with hepatitis C. 
Materials and Methods: The viral RNA was extracted from the serum of HCV infected patient. The 
NS3 helicase region was amplified by RT-PCR. The PCR product was directionally cloned into the 
expression vector pET102/D-TOPO and transformed into the BL21 strain of E. coli (DE3). The 
transformed bacteria were then induced by adding 1mM isopropyl-β-D-thiogalactopyranoside 
(IPTG) into the culture medium to enhance the protein expression. SDS-PAGE and western blotting 
were carried out to identify the protein under investigation, and finally purified recombinant 
fusion protein was used as the antigen for ELISA method.  
Results: The insertion of the DNA fragment of the NS3 region into the expression vector was 
further confirmed by PCR and sequencing. SDS-PAGE analysis showed the successful expression of 
the recombinant protein of interest. Furthermore, immunoreactivity of fusion NS3 helicase was 
confirmed by ELISA and western blotting. 
Conclusion: It seems that this recombinant protein could be a useful source of antigen for future 
studies on HCV diagnosis and therapy. 
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Introduction 
Hepatitis C virus (HCV), the major agent of NANBH 
(non- A, non- B hepatitis), is a cause of chronic hepatitis, 
liver cirrhosis, and hepatocellular carcinoma. HCV is            
an enveloped virus which contains a single-strand, 
positive-sense RNA genome with 9.6 Kb lengths. More 
than 170 million people are infected with this virus, 
globally (1-8). Current antiviral therapy for this 
infection is a combination therapy of pegylated 
interferon alpha (IFN-α) with ribavirin, which is 
expensive, frequently ineffective, and associated with 
many side effects, too. In addition, currently there is no 
protective vaccine for hepatitis C (6). 
One of the key enzymes of HCV that plays an 
important role in infectivity of the virus is non-
structural 3 (NS3) helicase. This enzyme is a necessary 
factor for unwinding the HCV genome during the 
process of replication and translation of the viral 
genome (7, 9-12). Additionally, NS3 helicase is 
involved in the replication and virus assembly 
through interaction with NS5B (RNA dependent RNA 
polymerase) and core proteins of virus, respectively. 
On the other hand, because of the strong antigenicity 
of NS3 helicase, this protein is critical in anti-HCV 
diagnostic reagents (11, 13, 14). As a result, NS3 
helicase could be a promising target for diagnosis 
and therapy of hepatitis C (6, 7, 9, 14-17). 
To expand our knowledge about the NS3 helicase 
protein, including its immunoreactivity with 
monoclonal antibodies and  potential use in enzyme-
linked immunosorbent assay (ELISA) reagent for 
immunodiagnostic HCV detection in human sera, the 
goal of this work was focused on cloning and 
expression of the conserved fragment of this protein for 
using in new generations of ELISA kits. 
 
 
*Corresponding author: Zohreh Sharifi. Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, 
Iran. Tel: +98-21-88601515; Fax: +98-21-88601555; email: z.sharifi@ibto.ir  
Immunoreactivity and expression of NS3 helicase                                                                                          Sadri et al 
  
 Iran J Basic Med Sci, Vol. 18, No. 2, Feb 2015   
 
160 
Materials and Methods 
Reagents 
The expression vector (pET102/D-TOPO), Ni-
NTA purification system, anti-His Tag antibody, and 
HRP-conjugated anti human against IgG were 
purchased (Invitrogen, Frankfurt, Germany). Primers 
were synthesized by Metabion (Frankfurt, Germany). 
Micro bicinchoninic acid (BCA) protein assay Kit 
(Pierce, Rockford, United States) and Pfu DNA 
polymerase (Stratagene, La Jolla, United States) were 
provided. Viral Nucleic acid extraction Kit, PCR 
product purification Kit, and Plasmid extraction Kit 
all were obtained from Roche (Frankfurt, Germany). 
The Escherichia coli BL21 (DE3) strain was provided 
by virology laboratory of Iranian Blood Transfusion 
Organization. Polyvinylidene difluoride (PVDF) 
membrane and horseradish peroxidase (HRP) 
substrate for western blotting were obtained from 
Amersham (London, United Kingdom). 
 
RNA extraction and cDNA synthesis 
Viral RNA was extracted from the serum of a 
patient who was infected with HCV subtype 1a. RNA 
extraction was performed according to the 
manufacturer's instructions of the viral nucleic acid 
extraction Kit. Reverse transcription (RT) was 
performed on 5 µl of template RNA with 5.5 µl 
mixture of RT buffer, RNase Inhibitor, dNTP Mixture, 
random hexamer primer, and Moloney Murine 
Leukemia Virus enzyme (MMLV). Reaction was 
performed at 42°C for 1 hr and 72°C for 10 min in 
final step for inactivation of reverse transcriptase. 
 
PCR amplification and construction of 
recombinant plasmid 
To amplify the NS3 helicase of HCV, PCR was 
carried out on the synthesized cDNA. The conserved 
region was selected for designing the primers. 
Nested PCR was performed with outer (F: 5' GTG 
GAG TGG CTA AGG CGG TGG A 3' and R: 5' GTT GAG 
TGC GGG AGA CAG CAT CCT 3') and inner (F: 5'CAC 
CAT GAG CTT CCA GGT GGC CC 3' and R: 5'GAC ACA 
CGT GTT GCA GTC TAT CA 3') primers. To enable 
directional cloning with pET102/D-TOPO, the 
“CACC” sequence was added at the 5' end of inner 
forward primer. Total volume of PCR reaction was 
100 µl, containing 2 µl Pfu DNA polymerase, 0.6 µl 
(100 pmol/µl) of each of the forward and reverse 
primers, 5 µl of 10X reaction buffer, 4 µl dNTPs             
(10 mM), 8 µl template, and sterile water which was 
added into the mixture to 100 µl. PCR products of the 
first round of PCR were used as the template for the 
second round of PCR. PCR was performed according 
to the following program: initial denaturation at 94°C 
for 2 min, 40 cycles containing denaturation at 94°C 
for 45 sec, annealing at 58°C in first round of PCR and 
59°C in second round of PCR for 10 sec, extension at 
72°C for 2 min, and the last final extension at 72°C for 
10 min. After electrophoresis using 1.5% agarose gel 
containing ethidium bromide, final PCR product was 
visualized under a UV transilluminator. PCR product 
was purified with PCR product purification Kit, and 
ligated with pET102/D-TOPO expression vector 
according to the standard protocol of the Kit. N-
terminal His-patch thioredoxin and His- Tag 
fragment of pET102/D-TOPO vector were also 
expressed with NS3 fragment to increase the 
solubility and purify of it, respectively (18). 
The ligation product was transformed into E. coli 
BL21 (DE3) strain containing T7 polymerase gene for 
expression of the recombinant plasmid and 
subsequently these bacteria were cultured in Luria 
Bertani (LB) agar plate containing 100 µg/ml of 
ampicillin. For confirmation of the cloning of 
recombinant plasmid, PCR and DNA sequencing 
techniques were performed. 
 
Expression and purification of recombinant 6His-
NS3 protein 
E. coli BL21 (DE3) cells carrying recombinant 
plasmid were inoculated into LB-broth containing 
100 µg/ml ampicillin and allowed to grow in a 
shaker incubator at 37°C overnight. Once an optical 
density (OD) of the culture at 600 nm reached to 0.6, 
induction was performed by addition of 1 mM IPTG 
(isopropyl-L-D-thiogalactoside) and allowed to grow 
for 5 more hr at 37°C in a shaker incubator. After this 
time, bacterial culture was centrifuged at 8,000 rpm 
for 10 min. Then, the pellet was resuspended in lysis 
buffer (50 Mm Tris HCL, 30 mM NaCl, pH 7.6) 
containing cocktail of protease inhibitor and 
subsequently sonicated for 20 cycles of 30 sec with 
30 sec of incubation on ice between pulses. In the 
next step, sonicated bacteria were centrifuged at 
14,000 rpm for 10 min at 4°C. The supernatant was 
purified using Ni-NTA purification system under 
denaturing conditions. The collected elution was 
analyzed by performing BCA assay to determine the 
expression yield of the recombinant protein and was 
applied for western blot and ELISA tests. 
 
Western blotting 
Protein samples, including recombinant 6His-NS3 
helicase, were prepared, loaded in 12% SDS-PAGE 
gel, and run to separate. The protein bands were 
transferred onto PVDF membrane. Subsequently, the 
membrane was incubated at room temperature (RT) 
for 1.5 hr with blocking buffer (5% non-fat dry milk 
in TBS-Tween); then, it was incubated with the HCV 
positive serum (with a pool sera from antigens of 1a, 
1b, and 3a genotypes) as the primary antibody 
diluted 1:15000 in the blocking buffer (3% non-fat 
dry milk in TBS plus 0.1% Tween-20) at 4°C 
overnight. The membrane was washed with TBST 
(TBS plus 0.1% Tween 20) once for 15 min and three 
times for five min. After washing, the membrane 
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Figure 1. PCR amplification of NS3 helicase 
Lane 1:100 bp DNA ladder, lane 2: PCR product of NS3 helicase 
fragment 
 
was incubated with HRP-conjugated rabbit anti-
human IgG, diluted 1:80,000 in TBST containing 3% 
non-fat dry milk for 1 hr at RT. Again, washing of the 
membrane was performed as mentioned before; 
then, it was incubated with chemiluminescent HRP 
substrate for five min at RT. Finally, the produced 
light from the luminescent chemical reactions was 
recorded on a film. 
In a parallel experiment, western blot analysis 
was performed on the recombinant protein with 
anti-His tag monoclonal antibody (diluted 1:2000). 
This antibody specifically binds to His-tag fusion of 
recombinant protein and confirms the presence of 
the protein of interest. 
 
ELISA 
The purified recombinant protein was used as the 
antigen coating the ELISA strips in order to test sera 
in an ELISA format. The wells of microplates were 
coated with 100 µl of the antigen (5 µg/ml) in 100 
mM sodium carbonate buffer pH 9.6, at 4 °C 
overnight. Next day, the wells were washed three 
times with TBST and blocked with 200 µl of 5% BSA 
in TBS for 1 hr at 37°C. After three times washing 
with wash buffer, 100 µl of diluted serum (1:1000) 
was added in duplicate to the wells and was 
incubated for 30 min at 37°C. The wells were washed 
three times and subsequently incubated with 100 µl 
of HRP-conjugated goat anti-human IgG, diluted 
1:1000 for 30 min at 37°C. Washing the wells were 
performed four times, then 100 µl of the TMB 
substrate was added  to each well and incubated for 
20 min at 37°C, while microplates were coverslipped 
with foil. The reaction was stopped by adding 50 µl 
of 0.2 M H2SO4 and absorbance of the resulting 
yellow color was measured at 450 nm with the 
Biochrom Asys Expert 96 microplate reader.  
50 HCV positive sera, from different HCV 
subtypes (1a, 1b, and 3a), and 50 HCV negative sera 
were used in ELISA test 
 
Results 
PCR amplification and construction of recombinant 
plasmid 
The PCR products were analyzed on agarose gel 
in parallel with 100 bp DNA size marker. The 
expected 711 bp PCR product fragment was 
observed (Figure 1). The PCR product was ligated to 
pET102/D-TOPO expression vector and transformed 
into E. coli BL21 (DE3) strain. The recombinant 
plasmid was confirmed by PCR and sequencing 
analysis. The results of BLAST search in NCBI 
showed that the determined sequence has 95% 
similarity with a HCV subtype 1a with the accession 
number EU687194. 
 
Expression and identification of recombinant protein 
Bacterial culture containing the recombinant 
plasmid was induced by 1 mM IPTG once the OD 
(600 nm) reached 0.6. After five hr shaking the 
medium at 37°C, SDS-PAGE and western blotting 
were done. Western blot assay was performed using 
both HCV positive serum and anti His-tag antibody as 
a primary antibody. The results clearly have shown 
the expression of recombinant NS3 helicase protein 
in comparison with the control well (Figure 2). 
Additionally, the results of the western blotting using 
HCV positive serum as the primary antibody 
confirmed that the recombinant NS3 helicase 
strongly reacted with anti-HCV antibodies in the 
serum of HCV infected patient. 
 
 
 
 
 
Figure 2. Western blotting of NS3 helicase protein was performed 
with HCV positive serum as primary antibody. lane1: Total protein 
of Escherichia coli BL21 as negative control; lane2: Total protein of 
E. coli BL21 carrying pET102-NS3 without IPTG induction; lane 3, 
5: The purified NS3 from E. coli BL21 transforming with pET102-
NS3 using infected serum and His-tag antibody respectively; lane 
4: Total protein of E. coli BL21 Carrying pET102-NS3 after IPTG 
induction for 5 hr at 37°C; lane M: molecular weight markers 
Immunoreactivity and expression of NS3 helicase                                                                                          Sadri et al 
  
 Iran J Basic Med Sci, Vol. 18, No. 2, Feb 2015   
 
162 
ELISA 
The purified NS3 protein was used as a potential 
antigen to set up the ELISA method for studying the 
immunoreactivity of Iranian HCV patient sera. ELISA 
test was performed on 50 positive samples from 
different HCV subtypes (1a, 1b, and 3a). The 
obtained results from these experiments showed 
that 80% of positive samples were above the cutoff 
value calculated from the data which were obtained 
from negative samples. Among these 80% positive 
samples, 1a genotype with more than 75% frequency 
has the highest reactivity compared to other 
genotypes (1b and 3a). 
 
Discussion 
Hepatitis C referred to a “silent disease” is often 
asymptomatic infection. Therefore, detection and 
treatment of this disease in the early stage is critical. 
Because of the important role of the NS3 helicase in 
viral replication and also its antigenicity due to 
highly conserved epitopes of this region, this protein 
fragment could be a promising target for developing 
new therapeutic agents (7, 14, 17, 19). Additionally, 
NS3 helicase protein is a key antigen in anti-HCV 
diagnostic kits (5, 9). In one study, a recombinant 
fusion protein 6-His NS3 helicase was used as an 
antigen to produce monoclonal antibodies MAbs 
specific for HCV NS3 helicase. Their results showed 
that NS3 helicase activity could be inhibited by a 
concentration of these MAbs in a nanomolar range 
(8). The helicase NS3 belongs to superfamily 2 (SF2) 
of the Non-ring helicase group (9). This portion of 
HCV forms three domains and contains a number of 
highly conserved helicase motifs. These conserved 
regions line the cleft between the domain 1 and 2 
(20). These domains (1 and 2) are tandem repeats on 
the translated polypeptide and form a molecular 
motor. Structural and biochemical studies have 
shown that movement of these domains during the 
NS3 activity process, initiates the moving of the 
helicase along nucleic acids and eventually 
unwinding the strand (9). Also, studies suggest that 
ATP binding site is likely located in the cleft between 
domain 1 and 2 (which is referred as RecA-like 
motor domains) (9). 
In this research, a fragment of NS3 helicase, 
contained domain 1 and domain 2, was cloned into 
pET102/D-TOPO expression vector and induced by 
IPTG to express the recombinant protein in BL21 (DE3) 
strain of E. coli. This vector contains a tagged 
polyhistidine region at C-termini of the recombinant 
protein and used for purification by Ni-NTA affinity 
column; In addition, this region is useful for detection of 
the fusion protein with anti His-tag monoclonal 
antibodies in western blotting. Using pET102/D-TOPO 
expression vector helps us to get a considerable 
amount of expressed protein for appraising and 
studying in other steps of the project. In another 
experiment that infected Iranian patients sera (subtype 
1a) was applied as the primary antibody, a high 
antigenicity of this NS3 helicase region was seen. 
Although, the predicted molecular mass of the 
expressed NS3 fragment was around 26.1 kDa, 
because of the molecular weight of His-patch 
sequence (has about 16 kDa) and His-tag which 
added around 1 kDa to the fused protein, the total 
molecular mass of the expressed recombinant 
protein raised to around 43.4 kDa. Considering the 
obtained results from subtype 1a, we tested 50 
positive sera samples from different HCV subtypes 
(1a, 1b, 3a, etc) by means of ELISA method. The 
results showed that 80% of the samples were 
immunoreactive.  
In new generations of HCV diagnostic kits more 
than three antigens (from nonstructural 3, 
nunstructural 4, nunstructural 5, and core genes) are 
used for increasing the sensitivity of the test to reach 
about 100% (21, 22). Because these antigens represent 
in the early stages of infection with HCV; thus, having 
80% sensitivity in just one of these antigens used in 
diagnostic kits could be promising to develop new 
generations of HCV detection kits (21). 
 
Conclusion 
The results of the present study showed that NS3 
helicase fragment of HCV was successfully cloned 
and expressed in E. coli BL21 (DE3) using pET102/D-
TOPO expression vector. Noticing to the past reports 
which tried different approaches such as production 
of human single-chain antibody (sFV) fragment as 
intracellular antibodies and intrabodies to inhibit the 
HCV NS3 helicase or use of HCV NS3, core, and E1 
epitopes to produce a novel combined vaccine, it can 
be suggested that using the expressed protein from 
domains (1 and 2) of HCV NS3 helicase would be a 
promising target for future. This recombinant 
protein was proposed to be used as an efficient 
protein fragment to design new therapeutic 
antibodies; while, it can also be considered as an 
important antigen in HCV immunodiagnosis assays. 
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